title: Weighing the risks and benefits of Pneumocystis pneumonia prophylaxis in iatrogenically immunosuppressed dermatology patients.
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, MN, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Julia S
authors.initials: JS
authors.lastname: Lehman
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Tania M
authors.initials: TM
authors.lastname: Gonzalez Santiago
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Wetter
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, MN, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Amer N
authors.initials: AN
authors.lastname: Kalaaji
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Limper
mesh_terms: D000072085:Dermatologists; D003880:Dermatology; D006801:Humans; D016867:Immunocompromised Host; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D018570:Risk Assessment